PT809653E - Anigenio de helicobacter pylori - Google Patents
Anigenio de helicobacter pylori Download PDFInfo
- Publication number
- PT809653E PT809653E PT96902390T PT96902390T PT809653E PT 809653 E PT809653 E PT 809653E PT 96902390 T PT96902390 T PT 96902390T PT 96902390 T PT96902390 T PT 96902390T PT 809653 E PT809653 E PT 809653E
- Authority
- PT
- Portugal
- Prior art keywords
- pylori
- protein
- antigenic fragment
- composition
- antigen
- Prior art date
Links
- 241000590002 Helicobacter pylori Species 0.000 title description 5
- 229940037467 helicobacter pylori Drugs 0.000 title description 5
- 230000000890 antigenic effect Effects 0.000 claims abstract description 37
- 102000036639 antigens Human genes 0.000 claims abstract description 34
- 108091007433 antigens Proteins 0.000 claims abstract description 34
- 239000000427 antigen Substances 0.000 claims abstract description 33
- 239000012634 fragment Substances 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 12
- 238000003745 diagnosis Methods 0.000 claims abstract description 11
- 229960005486 vaccine Drugs 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 30
- 238000001514 detection method Methods 0.000 claims description 14
- 108010046334 Urease Proteins 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 238000005227 gel permeation chromatography Methods 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000012790 confirmation Methods 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 12
- 238000012360 testing method Methods 0.000 description 11
- 230000028327 secretion Effects 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012609 strong anion exchange resin Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9502899.9A GB9502899D0 (en) | 1995-02-15 | 1995-02-15 | Novel antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT809653E true PT809653E (pt) | 2002-03-28 |
Family
ID=10769595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT96902390T PT809653E (pt) | 1995-02-15 | 1996-02-15 | Anigenio de helicobacter pylori |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0809653B1 (de) |
| JP (1) | JPH11503999A (de) |
| KR (1) | KR19980701698A (de) |
| CN (1) | CN1175955A (de) |
| AT (1) | ATE206138T1 (de) |
| AU (1) | AU714222B2 (de) |
| CA (1) | CA2212952A1 (de) |
| DE (1) | DE69615537T2 (de) |
| DK (1) | DK0809653T3 (de) |
| ES (1) | ES2164231T3 (de) |
| FI (1) | FI973335A0 (de) |
| GB (1) | GB9502899D0 (de) |
| IL (1) | IL117151A (de) |
| NO (1) | NO973753D0 (de) |
| NZ (1) | NZ301334A (de) |
| PT (1) | PT809653E (de) |
| WO (1) | WO1996025430A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6599509B2 (en) | 1997-09-02 | 2003-07-29 | Massachusetts Institute Of Technology | Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease |
| CN1105185C (zh) * | 1998-11-30 | 2003-04-09 | 上海晶莹生物技术有限公司 | 基因表达幽门螺杆菌细胞毒素相关基因a蛋白抗原制备工艺 |
| AUPQ854100A0 (en) * | 2000-07-03 | 2000-07-27 | Helirad Pty Ltd | Methods for monitoring treatment of helicobacter infection |
| SE0101030D0 (sv) * | 2001-03-23 | 2001-03-23 | Nordic Bio Ab | Immunogenic cell surface proteins of helicobacter pylori |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5459041A (en) * | 1988-02-18 | 1995-10-17 | Enteric Research Laboratories, Inc. | Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection |
| DE4139840B4 (de) * | 1990-12-04 | 2005-06-02 | Quidel Corp., San Diego | Antigen-Zubereitung zum Nachweis von H. pylori |
| EP0638175B1 (de) * | 1992-04-29 | 1998-06-17 | Auspharm International Limited | In vitro-test für helicobacter pylori |
-
1995
- 1995-02-15 GB GBGB9502899.9A patent/GB9502899D0/en active Pending
-
1996
- 1996-02-15 AT AT96902390T patent/ATE206138T1/de not_active IP Right Cessation
- 1996-02-15 ES ES96902390T patent/ES2164231T3/es not_active Expired - Lifetime
- 1996-02-15 DE DE69615537T patent/DE69615537T2/de not_active Expired - Fee Related
- 1996-02-15 CN CN96191969A patent/CN1175955A/zh active Pending
- 1996-02-15 IL IL11715196A patent/IL117151A/en not_active IP Right Cessation
- 1996-02-15 NZ NZ301334A patent/NZ301334A/xx unknown
- 1996-02-15 JP JP8524773A patent/JPH11503999A/ja active Pending
- 1996-02-15 WO PCT/GB1996/000351 patent/WO1996025430A1/en not_active Application Discontinuation
- 1996-02-15 PT PT96902390T patent/PT809653E/pt unknown
- 1996-02-15 KR KR1019970705094A patent/KR19980701698A/ko not_active Application Discontinuation
- 1996-02-15 DK DK96902390T patent/DK0809653T3/da active
- 1996-02-15 AU AU46728/96A patent/AU714222B2/en not_active Ceased
- 1996-02-15 EP EP96902390A patent/EP0809653B1/de not_active Expired - Lifetime
- 1996-02-15 CA CA002212952A patent/CA2212952A1/en not_active Abandoned
-
1997
- 1997-08-14 FI FI973335A patent/FI973335A0/fi unknown
- 1997-08-14 NO NO973753A patent/NO973753D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE206138T1 (de) | 2001-10-15 |
| DE69615537T2 (de) | 2002-04-18 |
| KR19980701698A (ko) | 1998-06-25 |
| FI973335A (fi) | 1997-08-14 |
| CN1175955A (zh) | 1998-03-11 |
| ES2164231T3 (es) | 2002-02-16 |
| NO973753L (no) | 1997-08-14 |
| EP0809653B1 (de) | 2001-09-26 |
| EP0809653A1 (de) | 1997-12-03 |
| DE69615537D1 (en) | 2001-10-31 |
| CA2212952A1 (en) | 1996-08-22 |
| IL117151A (en) | 2001-06-14 |
| WO1996025430A1 (en) | 1996-08-22 |
| DK0809653T3 (da) | 2001-11-19 |
| FI973335A0 (fi) | 1997-08-14 |
| GB9502899D0 (en) | 1995-04-05 |
| AU4672896A (en) | 1996-09-04 |
| AU714222B2 (en) | 1999-12-23 |
| IL117151A0 (en) | 1996-06-18 |
| JPH11503999A (ja) | 1999-04-06 |
| NZ301334A (en) | 1999-08-30 |
| MX9706267A (es) | 1997-11-29 |
| NO973753D0 (no) | 1997-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beachey et al. | Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. | |
| Riezu-Boj et al. | Comparison of lipopolysaccharide and outer membrane protein-lipopolysaccharide extracts in an enzyme-linked immunosorbent assay for the diagnosis of Brucella ovis infection | |
| AU663858B2 (en) | Diagnostic testing for campylobacter jejuni or coli infections using antigens | |
| Schønheyder et al. | IgG antibodies to purified Aspergillus fumigatus antigens determined by enzyme-linked immunosorbent assay | |
| WO1995009181A1 (fr) | Peptide contenant une sequences d'acides amines de la proteine de franges de porphyromonas gingivalis, et utilisation dudit peptide | |
| de Figueiredo Soares et al. | The interrelationship betweenHelicobacter pylorivacuolating cytotoxin and gastric carcinoma | |
| PT97150A (pt) | Novos metodos para o diagnostico da tuberculose | |
| PT809653E (pt) | Anigenio de helicobacter pylori | |
| Karamanos et al. | The Major 20-kDa Polysaccharide ofStaphylococcus epidermidisExtracellular Slime and Its Antibodies as Powerful Agents for Detecting Antibodies in Blood Serum and Differentiating among Slime-Positive and-NegativeS. epidermidisand other Staphylococci Species | |
| Wicher et al. | Cell response in rabbits infected with T. pallidum as measured by the leucocyte migration inhibition test. | |
| EP0975663A1 (de) | Helicobacter pylori antigene | |
| Seibert | A theory of immunity in tuberculosis | |
| US20020071850A1 (en) | Helicobacter pylori antigen | |
| Whittington et al. | An anamnestic serological test for ovine footrot | |
| MXPA97006267A (en) | Antigen of helicobacter pyl | |
| Nakagawa et al. | Reactive antibodies in sera from pubertal and adult gingivitis patients against various Porphyromonas gingivalis antigens | |
| Horsfall | The Diagnosis of Primary Atypical Pneumonia | |
| WO1994028927A1 (en) | Pasteurella haemolytica subunit vaccine containing capsular polysaccharide and muramyl dipeptide | |
| JPH02501768A (ja) | ブタ赤痢診断試験 | |
| Reitan et al. | Further characterization including preliminary chemical analysis of antigen MLW1 from Mycobacterium leprae | |
| PT87530B (pt) | Teste de diagnostico da sida com base na evidencia de uma diversidade da resposta isotipica | |
| WO2019097009A1 (en) | Vaccine compositions for use against digital dermatitis in a mammal | |
| Hauer | Identifying and purifying protective immunogens from cultures of Clostridium chauvoei | |
| Woods | Immunogenicity of Streptococcus equisimilis. | |
| Király | Immunoallergologic Aspects of Gonorrhoea |